secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001437749-24-035391
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Q3 net loss $8.4M; 108 patients complete 1-year OLE trial for brilaroxazine
--------------------------------------------------------------------------------

- Net loss of $8.4M ($0.25/sh) for Q3 2024 vs $11.3M ($0.48/sh) in Q3 2023 (restated).
- Cash totaled $5.6M as of Sep 30, 2024, down from $23.4M at Dec 31, 2023.
- 108 patients have completed 1 year of treatment in brilaroxazine OLE trial; topline data expected December 2024.
- NDA submission for brilaroxazine in schizophrenia targeted for Q2 2026; RECOVER-2 start expected Q1 2025 pending financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/0001437749-24-035391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/rvph20241107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer